Results 71 to 80 of about 57,284 (206)

Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease

Biomolecules, 2018
The mineralocorticoid receptor (MR) was first identified as a blood pressure regulator, modulating renal sodium handling in response to its principal ligand aldosterone.
Stefania Gorini, Vincenzo Marzolla, Caterina Mammi, Andrea Armani, Massimiliano Caprio   +4 more
doaj   +1 more source

Mineralocorticoid receptor blockade during a rat's first violent encounter inhibits its subsequent propensity for violence. [PDF]

, 2013
In individuals naive to serious conflict in an unfamiliar environment, violence has long-lasting effects on subsequent aggressive behavior. This effect of the stressful experience of a first violent conflict occurs in victims as well as offenders.
Haller, József, Kloet, E. R., Kruk, M. R., Meelis, W.   +3 more
core   +1 more source

The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome [PDF]

, 2019
When hypertension, a pathology that is frequently found in the general population, presents in a young patient, secondary causes such as Cushing's syndrome (CS), a rare disease characterized by long-term elevated cortisol levels, should be considered ...
Barbot, Mattia, Ceccato, Filippo, Scaroni, Carla   +2 more
core   +1 more source

Aldosterone receptor antagonists: current perspectives and therapies

Vascular Health and Risk Management, 2013
Jason L Guichard, Donald Clark III, David A Calhoun, Mustafa I Ahmed University of Alabama at Birmingham, Department of Medicine, Division of Cardiovascular Disease, Vascular Biology and Hypertension Program, Birmingham, AL, USA Abstract: Aldosterone is ...
Guichard JL, Clark III D, Calhoun DA, Ahmed MI   +3 more
doaj  

A rare case of apparent mineralocorticoid excess induced by chronic liquorice ingestion

Endocrinology, Diabetes & Metabolism Case Reports
Apparent mineralocorticoid excess (AME) syndrome is a rare condition caused by the inhibition of the renal enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). The most common acquired cause is chronic liquorice ingestion.
Aparajita Roy, Kieran Mullins
doaj   +1 more source

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B., Kothny, Wolfgang, Kozlovski, Plamen, Krum, Henry, Lewsey, James D., Lukashevich, Valentina, McMurray, John J.V., Ponikowski, Piotr   +7 more
core   +2 more sources

Campylobacter concisus Impairs Sodium Absorption in Colonic Epithelium via ENaC Dysfunction and Claudin-8 Disruption [PDF]

, 2020
The epithelial sodium channel (ENaC) can increase the colonic absorptive capacity for salt and water. Campylobacter concisus is a common pathogenic epsilonproteobacterium, causing enteritis and diarrhea. It can induce barrier dysfunction in the intestine,
Bereswill, Stefan, Butkevych, Eduard, Bücker, Roland, Fromm, Anja, Genger, Claudia, Heimesaat, Markus M., Kløve, Sigri, Lee, In-Fah Maria, Lobo de Sá, Fábia Daniela, Mousavi, Soraya, Nagel, Oliver, Nattramilarasu, Praveen Kumar, Nielsen, Hans Linde, Schulzke, Jörg-Dieter, Schweiger, Michal R., Troeger, Hanno   +15 more
core   +2 more sources

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. [PDF]

, 2016
AimsIn this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril ...
Claggett, Brian, Desai, Akshay S, Lefkowitz, Martin, McMurray, John JV, Packer, Milton, Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators, Rouleau, Jean, Shi, Victor, Solomon, Scott D, Swedberg, Karl, Teerlink, John R, Vardeny, Orly, Zile, Michael R   +12 more
core   +1 more source

Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases [PDF]

, 2004
Fluticasone propionate - the first carbothioate corticosteroid - has been classified as a potent anti-inflammatory drug for dermatological use. It is available as 0.05% cream and 0.005% ointment formulations for the acute and maintenance treatment of ...
Atsuta J, Boner AL, Bridgman A, Callen J, Delescluse J, Dooms-Goossens AE, Dykes PJ, Falcoz C, Fisher DA, Goossens A, Harding SM, Hogger P, James M, Johnson M, Johnson M, Juhlin L, Katz HI, Korting HC, Lebwohl M, Li JT, Liu XQ, Llewellyn-Jones CG, Lucky AW, McKenzie AW, McLean HM, Nurnberger FG, Phillipps GH, Roberts DT, Spencer CM, Tharp MD, Venning VA, Wilkinson SM, Wolkerstorfer A, Young MMR   +33 more
core   +1 more source

Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?

Kidney & Blood Pressure Research
Background: Aldosterone is the principal mineralocorticoid hormone and the final effector of the renin-angiotensin-aldosterone system. This hormone is primarily synthesized by the CYP11B2 enzyme and produced by the adrenal zona glomerulosa ...
Alessio Mazzieri, Francesca Timio, Francesco Patera, Francesco Trepiccione, Mario Bonomini, Gianpaolo Reboldi   +5 more
doaj   +1 more source